A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/09/2006	US20060252804 Flupirtin injectable galenic form
11/09/2006	US20060252803 Hydrogenation of precursors to thiazolidinedione antihyperglycemics
11/09/2006	US20060252802 Small molecule cyclin D1 ablative agents
11/09/2006	US20060252801 Small molecule Bcl-xL/Bcl-2 binding inhibitors
11/09/2006	US20060252800 Anti-leishmania agent
11/09/2006	US20060252799 Benzo (F) insoindol derivatives and their use as EP4 receptor ligands
11/09/2006	US20060252798 Metal ion chelators and therapeutic use thereof
11/09/2006	US20060252797 Receptor regulator
11/09/2006	US20060252796 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle; selective androgen receptor modulators; decrease excess sebum secretions; stimulants of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer
11/09/2006	US20060252795 Chemokine receptor binding heterocyclic compounds
11/09/2006	US20060252794 Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist
11/09/2006	US20060252793 Useful as adjuvants to chemotherapy or radiation therapy to treat cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2); 2-[4-(3,4-dichloro-phenoxy)-phenyl]-1H-imidazo[4,5-b]pyridine-5-carboxylic acid amide
11/09/2006	US20060252792 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors
11/09/2006	US20060252791 Imidazo[4,5-c]pyridine compound and method of antiviral treatment
11/09/2006	US20060252790 e.g. 5-{5-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1,3,4-oxadiazol-2-yl}-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine; antiinflammatory agent, antiallergen; cognitive impairment; asthma, arthritis
11/09/2006	US20060252789 Amorphous moxifloxacin hydrochloride
11/09/2006	US20060252788 Methods and compositions for the treatment of CNS-related conditions
11/09/2006	US20060252787 Phospholipid transfer protein (PLTP) and cholesterol metabolism
11/09/2006	US20060252786 Nicotinic-opioid synergy for analgesia
11/09/2006	US20060252785 Heterocyclic antiviral compounds
11/09/2006	US20060252784 Imidazo-substituted 1,8-naphthyridinylamines; treating arthritis, Crohn's disease, Alzheimer's disease, irritable bowel syndrome, adult respiratory distress syndrome, and chronic obstructive pulmonary disease.
11/09/2006	US20060252783 Imidazo-substituted pyrido[2,3-d]pyrimidinylamines; treating arthritis, Crohn's disease, Alzheimer's disease, irritable bowel syndrome, adult respiratory distress syndrome, and chronic obstructive pulmonary disease.
11/09/2006	US20060252782 Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same
11/09/2006	US20060252781 Fused heterocycles as inhibitors of glutamate racemase(muri)
11/09/2006	US20060252780 Fused pyrimidine derivatives
11/09/2006	US20060252779 (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine
11/09/2006	US20060252778 Compounds for the treatment of inflammatory disorders
11/09/2006	US20060252777 5-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-(4-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one; anticarcinogenics, antimetastasis agents, antiproliferatives, angiogenesis inhibitors; hepatocyte growth factor mediated diseases
11/09/2006	US20060252776 Novel crystalline forms of valacyclovir hydrochloride
11/09/2006	US20060252775 Methods for reducing levels of disease associated proteins
11/09/2006	US20060252774 Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
11/09/2006	US20060252773 Method for the treatment of drug abuse
11/09/2006	US20060252772 Novel crystalline forms of gatifloxacin and processes for preparation
11/09/2006	US20060252771 Novel crystalline forms of gatifloxacin and processes for preparation
11/09/2006	US20060252770 Novel crystalline forms of gatifloxacin and processes for preparation
11/09/2006	US20060252769 Obesity, type 2 diabetes, sleep disorders, ischaemic or haemorrhagic strokes, antiemetic; toxicity; side effect reduction; 2-((benzofuran-4-yl)carbonylaminomethyl)-1-((4-(5-(4-fluorophenyl)-2-methyl)thiazolyl)carbonyl)-4-methylpiperazine
11/09/2006	US20060252768 2,3,6-Trisubstituted-4-pyrimidone derivatives
11/09/2006	US20060252767 Piperazine derivatives and their use as therapeutic agents
11/09/2006	US20060252766 Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
11/09/2006	US20060252765 Corneal perception recovery drug containing amide compound
11/09/2006	US20060252764 HIV inhibiting pyrimidines derivatives
11/09/2006	US20060252763 Treatment of von hippel lindau disease
11/09/2006	US20060252762 Methods for treatment of multiple sclerosis
11/09/2006	US20060252761 Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
11/09/2006	US20060252760 Farnesyl transferase inhibitors
11/09/2006	US20060252759 (5R,8aR)-5-methyl-1,3,5,6,7,8,8a,9-octahydro-2-oxa-4,4b,7-triaza-cyclopenta[b]fluorene; serotonin (5HT2C) receptor agonists; reductiv amination, acylation
11/09/2006	US20060252758 sodium channel modulators such as 1'-pentylspiro[furo[2,3-f][1,3]benzodioxole-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one, useful as for the treatment of nervous system disorders, cardiovascular disorders, muscular disorders and as neuroprotectants or as analgesics
11/09/2006	US20060252757 such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs)
11/09/2006	US20060252756 Azolo triazines and pyrimidines
11/09/2006	US20060252755 E.g., 3-(3-benzylphenyl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1,2,4-triazin-6(1H)-one and 3-{3-[(Z)-(Methoxyimino)phenyl)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1,2,4-triazin-6(1H)-one; broad spectrum
11/09/2006	US20060252754 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
11/09/2006	US20060252753 N-methyl-N-[2-( 1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride;
11/09/2006	US20060252752 Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects
11/09/2006	US20060252751 specific compound N-(2-{[(3R)-1-(4-hydroxy-4-pyrimidin-4-ylcyclohexyl)pyrrolidin-3-yl]amino}-2-oxoethyl)-3-(trifluoromethyl)benzamide; multiple sclerosis; CCR2 and/or CCR5 antagonists
11/09/2006	US20060252750 1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes
11/09/2006	US20060252749 Lacosamide for add-on therapy of psychosis
11/09/2006	US20060252748 Use of CDK II inhibitors for birth control
11/09/2006	US20060252747 Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists
11/09/2006	US20060252746 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
11/09/2006	US20060252745 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
11/09/2006	US20060252744 Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
11/09/2006	US20060252743 Method of treating sleep disorders
11/09/2006	US20060252742 prostaglandin receptor agonists; for treating various ocular hypertensive conditions such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts
11/09/2006	US20060252741 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
11/09/2006	US20060252740 Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
11/09/2006	US20060252739 Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
11/09/2006	US20060252738 Method for preparing and using water-based steroid pheromone compositions
11/09/2006	US20060252737 18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
11/09/2006	US20060252736 Process for producing unsaturated fatty acid-containing oils
11/09/2006	US20060252735 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
11/09/2006	US20060252734 Testing a woman's blood to make sure it includes estradiol within a predetermined range and testosterone within a second predetermined range, then administrating a drug selected from the group consisting of vardenafil hydrochloride and tadalafil prior to sexual activity; dehydroepiandrosterone (DHEA)
11/09/2006	US20060252733 Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
11/09/2006	US20060252732 Blood vessel-growth promoter
11/09/2006	US20060252731 Methods of treating recurrent aphthous stomatitis
11/09/2006	US20060252730 Adenosine receptor antagonists and methods of making and using the same
11/09/2006	US20060252729 Nucleobase phosphonate analogs for antiviral treatment
11/09/2006	US20060252727 Medicinal compositions and therapeutic methods for treating arthritis and other painful conditions
11/09/2006	US20060252726 Composition and method for treating nosebleeds
11/09/2006	US20060252725 Use of prebiotics for preventing or treating oxidation stress
11/09/2006	US20060252723 Combined therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon
11/09/2006	US20060252718 Sphingolipids polyalkylamine conjugates for use in transfection
11/09/2006	US20060252717 Sphingoid polyalkylamine conjugates for vaccination
11/09/2006	US20060252716 Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
11/09/2006	US20060252715 Tricyclic-nucleoside compounds for treating viral infections
11/09/2006	US20060252714 Pharmaceutical compositions and methods for treating multidrug resistant cancer
11/09/2006	US20060252713 Semisynthetic macrolides; bacterial infections; of upper respiratory tract infections and lower respiratory tract infections; good pharmacokinetic properties and acid stability while continuing to be active against H. influenzae; overcome the problem of pneumococcal resistance
11/09/2006	US20060252712 6-11 Bridged oxime erythromycin derivatives
11/09/2006	US20060252711 Method and medicament for treating ocular infections
11/09/2006	US20060252710 Bicyclic 12 lactone ring macrolide, ketolide, and anhydrolide derivatives; antibacterial; cystic fibrosis
11/09/2006	US20060252709 Novel semisynthetic macrolide antibiotics of the azalide series
11/09/2006	US20060252708 Compositions of flavones and long chain fatty acid derivatives isolated from plants and methods related thereto for the control of prostate disorders
11/09/2006	US20060252707 Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
11/09/2006	US20060252706 Composition for slimming
11/09/2006	US20060252705 Sterol glucoside toxins
11/09/2006	US20060252704 Bevirimat dimeglumine (DSB*2NMG) crystal forms; HIV
11/09/2006	US20060252703 Method for treating cancer
11/09/2006	US20060252702 Method of improving cerebral function
11/09/2006	US20060252700 Immunomodulator
11/09/2006	US20060252699 Administering dipeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; tripeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; alpha-ketobutyrate; propionyl A CoA, and combinations thereof
11/09/2006	US20060252696 Pharmaceutical composition as solid dosage form and method for manufacturing thereof

1 ... 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 ... 7860